ABSTRACT

Introduction: Piperacillin/Tazobactam, a broad-spectrum antibiotic combining ureidopenicillin and ?- lactamase inhibitor, is used as an empirical therapy for several infections that may increase the threat of antimicrobial resistance. Drug utilization evaluation (DUE) helps in detecting inappropriate drug use and promoting rational treatment. DUE increases the role of clinical pharmacists in better analyzing drug- related issues and providing appropriate pharmacist interventions. Aim and objective: To evaluate the utilization of Piperacillin/Tazobactam in a major tertiary teaching hospital. Methodology: A prospective study was conducted with a total of 500 patients, which was divided into two phases: pre-intervention and post-intervention of each 250 subjects. In phase I, the first 250 cases were collected and evaluated. In phase II, the educational intervention was made, and the next 250 cases were collected and assessed. The collected data from both phases were compared by using a self-developed scoring system, JANS B-10. Result: Phase I result shows 200 cases (80%) partially appropriate, 49 cases (19.6%) appropriate, and case1 (0.4%) inappropriate. In phase II, 181 cases (72.4%) partially appropriate, 68 cases (27.2%) appropriate, and 1 case(0.4%) inappropriate were found. The overall assessment of appropriateness, using the JANS B-10 scoring system, demonstrated an improvement from 19.6% in Phase I to 27.2% in Phase II after educational intervention. Conclusion: The study found that drug utilization evaluation improved the appropriate use of piperacillin/tazobactam, reducing inappropriate antibiotic consumption and enhancing effective use by patients from phase I to phase II. Keywords: Antibiotic stewardship team; appropriate; drug utilization evaluation; inappropriate; pharmacist intervention; piperacillin tazobactam
Publication date: 01/12/2025

https://ijbpas.com/pdf/2025/December/MS_IJBPAS_2025_9690.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.12.9690